Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

IMPORTANCE: Prior studies have shown that only a small proportion of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC) experience benefit from programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors given as monotherapy. There are data suggesting th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Oncol
Egile Nagusiak: Tolaney, Sara M., Barroso-Sousa, Romualdo, Keenan, Tanya, Li, Tianyu, Trippa, Lorenzo, Vaz-Luis, Ines, Wulf, Gerburg, Spring, Laura, Sinclair, Natalie Faye, Andrews, Chelsea, Pittenger, Jessica, Richardson, Edward T., Dillon, Deborah, Lin, Nancy U., Overmoyer, Beth, Partridge, Ann H., Van Allen, Eliezer, Mittendorf, Elizabeth A., Winer, Eric P., Krop, Ian E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2020
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489368/
https://ncbi.nlm.nih.gov/pubmed/32880602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3524
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak